×
Y-mAbs Therapeutics Share Holder Equity 2017-2024 | YMAB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Y-mAbs Therapeutics share holder equity from 2017 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
View More
Y-mAbs Therapeutics Share Holder Equity 2017-2024 | YMAB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Y-mAbs Therapeutics share holder equity from 2017 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$150.5B
Bristol Myers Squibb (BMY)
$118.1B
Vertex Pharmaceuticals (VRTX)
$115.4B
Gilead Sciences (GILD)
$109.4B
CSL (CSLLY)
$85.4B
Regeneron Pharmaceuticals (REGN)
$81.8B
GSK (GSK)
$69.3B
Argenex SE (ARGX)
$34.4B
Alnylam Pharmaceuticals (ALNY)
$30.2B
BioNTech SE (BNTX)
$25.5B
Biogen (BIIB)
$22.6B
Illumina (ILMN)
$21.4B
BeiGene (BGNE)
$18.3B
Moderna (MRNA)
$14.3B
Incyte (INCY)
$13.6B
Genmab (GMAB)
$13.6B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$11.8B
Vaxcyte (PCVX)
$10.9B
Bio-Techne Corp (TECH)
$10.5B
Sarepta Therapeutics (SRPT)
$10.2B
Exact Sciences (EXAS)
$10B
Exelixis (EXEL)
$9.8B
Revolution Medicines (RVMD)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
QIAGEN (QGEN)
$9.3B
Intra-Cellular Therapies (ITCI)
$8.8B
Roivant Sciences (ROIV)
$8.4B
Ascendis Pharma (ASND)
$7.5B
Repligen (RGEN)
$7.2B